Lawmaker Wants Answers About Warning Lag on Sarin Antidote Defects

Diane Barnes, Global Security Newswire
Add to Briefcase
See more stories about...
Diane Barnes, Global Security Newswire
Oct. 2, 2013, 3:02 a.m.

WASH­ING­TON — A U.S. law­maker said a sar­in-an­ti­dote man­u­fac­turer needs to ex­plain why it took over five months longer to in­form ci­vil­ian first re­spon­ders than De­fense De­part­ment of­fi­cials about de­fect­ive syr­inges used to ad­min­is­ter the nerve-agent treat­ment.

A thor­ough un­der­stand­ing of the drug com­pany’s lag in is­su­ing the warn­ings to the dif­fer­ent cus­tom­ers is cru­cial to pre­vent­ing any sim­il­ar no­ti­fic­a­tion delays in the fu­ture about drug de­fects, Rep­res­ent­at­ive An­drew Har­ris (R-Md.) told Glob­al Se­cur­ity News­wire.

The com­pany, a Pf­izer sub­si­di­ary named Me­ridi­an Med­ic­al Tech­no­lo­gies, no­ti­fied ci­vil­ian-emer­gency per­son­nel and whole­sale sup­pli­ers around the United States of the prob­lem­at­ic “DuoDote” syr­inges on Aug. 27, six days after a widely pub­li­cized sar­in-gas strike in Syr­ia’s civil war.

The Pentagon, though, had already been no­ti­fied five months earli­er about de­fects in sim­il­ar syr­inges that it bought from the com­pany to treat troops ex­posed to sar­in.

The Food and Drug Ad­min­is­tra­tion audited Me­ridi­an’s man­u­fac­tur­ing plant earli­er in March, and Pf­izer sub­sequently sus­pen­ded DuoDote pro­duc­tion to in­sti­tute new qual­ity con­trols at the fa­cil­ity, ac­cord­ing to Har­ris’ of­fice.  

Har­ris said a Wall Street Journ­al re­port­er in­formed him months later about the prob­lems, which im­pacted less than 1 per­cent of the ci­vil­ian and mil­it­ary “autoin­ject­or” syr­inges.

The law­maker — an an­es­thesi­olo­gist by train­ing — re­spon­ded by grilling Pf­izer in a let­ter last month on sev­er­al mat­ters tied to the prob­lem syr­inges.

“Me­ridi­an has thor­oughly answered all ques­tions but one: Why did it take al­most six months for the com­pany to no­ti­fy first re­spon­ders of the prob­lem?” Har­ris told Glob­al Se­cur­ity News­wire last week. “That is a ques­tion we must an­swer to make sure the delay does not hap­pen again.”

When quer­ied dir­ectly about the delay in alert­ing ci­vil­ian first re­spon­ders about the de­fect­ive syr­inges, Pf­izer said it needed time “to in­vest­ig­ate the is­sue and im­ple­ment cor­rect­ive ac­tion.”

The com­pany also stressed Wash­ing­ton has played a role in re­spond­ing to de­fects in the ci­vil­ian syr­inges.

“Me­ridi­an, work­ing in co­ordin­a­tion with the [Food and Drug Ad­min­is­tra­tion], and oth­er fed­er­al agen­cies needed to fully un­der­stand the im­plic­a­tions of the prob­lem,” com­pany spokes­man Chris­toph­er Loder told GSN in a state­ment.

The Pf­izer sub­si­di­ary, he said, “no­ti­fied [ci­vil­ian] cus­tom­ers once FDA-ap­proved in­struc­tions and guid­ance could be provided that would sup­port the safe use of the product.

The Food and Drug Ad­min­is­tra­tion, though, said Pf­izer made the de­cision about when to no­ti­fy ci­vil­ian hold­ers of DuoDote about the prob­lems, ac­cord­ing to the con­gress­man’s of­fice.

The later tim­ing of the no­tice to non­mil­it­ary groups might have con­trib­uted to ques­tions among some emer­gency per­son­nel about the avail­ab­il­ity of an­ti­dote for ci­vil­ian vic­tims of a po­ten­tial sar­in strike.

After Me­ridi­an aler­ted first re­spon­ders and oth­ers out­side the Pentagon to the syr­inge de­fects, FDA of­fi­cials ad­vised them to hold on to cer­tain DuoDote stocks for one year longer than their labeled ex­pir­a­tion dates. The nerve-agent an­ti­dote should re­tain its po­tency for the ex­tra time if stored as dir­ec­ted, the agency said in a Sept. 5 let­ter to med­ic­al per­son­nel and bulk re­tail­ers.

The FDA move ap­peared to be an at­tempt to com­pensate for the sus­pen­sion in DuoDote pro­duc­tion. However, some emer­gency re­spon­ders in­dic­ated they had already thrown away DuoDote that had aged out of its ori­gin­al four-year use peri­od. A Sept. 13 Journ­al art­icle notes that Ten­ness­ee au­thor­it­ies pulled lapsed doses of the drug from am­bu­lances be­fore the shelf-life ex­ten­sion in late sum­mer.

Back in Wash­ing­ton, Har­ris as of press time had yet to learn how Pf­izer’s sub­si­di­ary plans to deal with de­fect­ive syr­inges held by ci­vil­ian first re­spon­ders.

However, Loder said Pf­izer plans to “re­place or re­medi­ate” af­fected mil­it­ary an­ti­dote syr­inges that are still “with­in ex­piry,” and ad­ded that “Me­ridi­an ex­pects to reach the same agree­ment with [ci­vil­ian] pur­chasers of DuoDote.”

Har­ris told GSN last week that he planned to keep tabs on how the firm acts on its pledge to qual­ity-check the more than 2 mil­lion sar­in-an­ti­dote doses stocked by the De­fense De­part­ment.

“I be­lieve this prob­lem will be re­solved, and hope­fully it will be re­solved without any­one ever hav­ing to use the de­fi­cient dosage units be­fore they get re­placed,” the con­gress­man said.

Me­ridi­an has already sub­jec­ted 1.1 mil­lion mil­it­ary an­ti­dote syr­inges to phys­ic­al in­spec­tion and dis­carded any that lacked suf­fi­cient an­ti­dote, an un­named mil­it­ary of­fi­cial said in an art­icle by the Pentagon‘s Amer­ic­an Forces Press Ser­vice.

The United States in 2010 and 2012 awar­ded Me­ridi­an more than $250 mil­lion in nerve-gas-an­ti­dote con­tracts for the mil­it­ary alone, the Journ­al re­por­ted. The Obama ad­min­is­tra­tion last week an­nounced a new $60 mil­lion deal for Me­ridi­an to study how an ex­ist­ing sed­at­ive could treat seizures from nerve-agent ex­pos­ure.

What We're Following See More »
STARTS LEGAL FUND FOR WH STAFF
Trump to Begin Covering His Own Legal Bills
18 hours ago
THE DETAILS
DISCUSSED THE MATTER FOR A NEW BOOK
Steele Says Follow the Money
19 hours ago
STAFF PICKS

"Christopher Steele, the former British intelligence officer who wrote the explosive dossier alleging ties between Donald Trump and Russia," says in a new book by The Guardian's Luke Harding that "Trump's land and hotel deals with Russians needed to be examined. ... Steele did not go into further detail, Harding said, but seemed to be referring to a 2008 home sale to the Russian oligarch Dmitry Rybolovlev. Richard Dearlove, who headed the UK foreign-intelligence unit MI6 between 1999 and 2004, said in April that Trump borrowed money from Russia for his business during the 2008 financial crisis."

Source:
BRITISH PUBLICIST CONNECTED TO TRUMP TOWER MEETING
Goldstone Ready to Meet with Mueller’s Team
20 hours ago
THE LATEST

"The British publicist who helped set up the fateful meeting between Donald Trump Jr. and a group of Russians at Trump Tower in June 2016 is ready to meet with Special Prosecutor Robert Mueller's office, according to several people familiar with the matter. Rob Goldstone has been living in Bangkok, Thailand, but has been communicating with Mueller's office through his lawyer, said a source close to Goldstone."

Source:
SPEAKING ON RUSSIAN STATE TV
Kislyak Says Trump Campaign Contacts Too Numerous to List
20 hours ago
THE LATEST

"Russian Ambassador Sergey Kislyak said on Wednesday that it would take him more than 20 minutes to name all of the Trump officials he's met with or spoken to on the phone. ... Kislyak made the remarks in a sprawling interview with Russia-1, a popular state-owned Russian television channel."

Source:
“BLOWING A SURE THING”
Sabato Moves Alabama to “Lean Democrat”
1 days ago
WHY WE CARE
×
×

Welcome to National Journal!

You are currently accessing National Journal from IP access. Please login to access this feature. If you have any questions, please contact your Dedicated Advisor.

Login